W
WAVEMAN · COMPANY
ICCC · Immucell Corp /De/
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

ICCC

IMMUCELL CORP /DE/
PHARMA & BIOTECH · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · CIK 0000811641
C-SUITE BUYING · 1☆ WATCH
INSIDER NET · 180D
$76.0K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
13
13F, latest reported quarter
REVENUE GROWTH
+4.3%
XBRL, annual
NET MARGIN
-3.8%
CONVERSIONS · 180D
1
codes C/M, not in net · $146.0K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$76.0K over 180 days
+$76.0K over 90 days
more than 75% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
13 funds added or opened last quarter
below 78% of Pharma & Biotech
REVENUE
+4.3% year over year
more than 53% of Pharma & Biotech
MARGIN
-3.8% net margin
more than 62% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
0.2% of shares outstanding short · 1.0 days to cover · settled 2026-07-31
below 85% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +61.8%
+61.8%12M
-26%+12%+51%+90%2025-092025-102025-122026-032026-052026-072026-09 2026-06-18 · te Boekhorst Paul Francis Olivier bought $76.0K2025-12-03 · te Boekhorst Paul Francis Olivier bought $18.2K2025-12-02 · te Boekhorst Paul Francis Olivier bought $18.1K2025-12-03 · te Boekhorst Paul Francis Olivier bought $17.7K2025-12-04 · te Boekhorst Paul Francis Olivier bought $13.4K2025-12-03 · te Boekhorst Paul Francis Olivier bought $12.8K2025-11-25 · Tomsche David Scott bought $7.8K2025-11-25 · Tomsche David Scott bought $7.8K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $76.0K bought by insiders over 180 days, 13 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, IMMUCELL CORP /DE/ insiders bought a net $76.0K of stock across 10 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
te Boekhorst Paul Francis Olivier
President and CEO
BUY
2026-06-18
8,000.0
$76.0K
te Boekhorst Paul Francis Olivier
President and CEO
BUY
2025-12-04
2,432.0
$13.4K
te Boekhorst Paul Francis Olivier
President and CEO
BUY
2025-12-03
3,598.0
$18.2K
te Boekhorst Paul Francis Olivier
President and CEO
BUY
2025-12-03
2,556.0
$12.8K
te Boekhorst Paul Francis Olivier
President and CEO
BUY
2025-12-03
3,521.0
$17.7K
10 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 5 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
VANGUARD CAPITAL MANAGEMENT LLC
268,130.0 sh
$2.7M
MORGAN STANLEY
233,910.0 sh
$2.4M
RENAISSANCE TECHNOLOGIES LLC
171,089.0 sh
$1.7M
Cresset Asset Management, LLC
135,267.0 sh
$1.4M
GEODE CAPITAL MANAGEMENT, LLC
72,270.0 sh
$726.5K
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Nationwide Bailard Small Cap Value Fund
$85.5K POSITION · AS OF 2026-04-30
0.1%
iShares Micro-Cap ETF
$105.7K POSITION · AS OF 2026-03-31
0.0%
1290 VT Micro Cap Portfolio
$6.9K POSITION · AS OF 2026-03-31
0.0%
Small Cap Core Fund
$12.7K POSITION · AS OF 2026-03-31
0.0%
LVIP Dimensional U.S. Core Equity 2 Fund
$9.0K POSITION · AS OF 2026-03-31
0.0%
U.S. Social Core Equity 2 Portfolio
$17.8K POSITION · AS OF 2026-04-30
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$27.6M$26.5M$17.5M$18.6M
GROSS PROFIT$11.4M$7.9M$3.9M$7.6M
OPERATING INCOME$1.6M$-1.6M$-5.7M$-2.3M
NET INCOME$-1.0M$-2.2M$-5.8M$-2.5M
EPS (DILUTED)-0.12-0.26-0.75-0.32
OPERATING CASH FLOW$2.5M$357.9K$-4.7M$-1.5M
CASH$3.8M$3.8M$978.7K$5.8M
LONG-TERM DEBT$7.5M$9.0M$10.2M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →